Last reviewed · How we verify
Patiromer Oral Product
Patiromer Oral Product is a Potassium binder Small molecule drug developed by Wake Forest University Health Sciences. It is currently FDA-approved for Hyperkalemia in patients with chronic kidney disease or heart failure on renin-angiotensin-aldosterone system inhibitors. Also known as: Valtressa.
Patiromer is a non-absorbed potassium binder that sequesters potassium in the gastrointestinal tract to reduce serum potassium levels.
Patiromer is a non-absorbed potassium binder that exchanges sodium for potassium in the gastrointestinal tract, reducing serum potassium levels. Used for Hyperkalemia (elevated serum potassium levels).
At a glance
| Generic name | Patiromer Oral Product |
|---|---|
| Also known as | Valtressa |
| Sponsor | Wake Forest University Health Sciences |
| Drug class | Potassium binder |
| Target | Potassium ion (K+) in gastrointestinal lumen |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | FDA-approved |
Mechanism of action
Patiromer is a cation exchange polymer that binds potassium ions in the colon through ionic interactions, preventing potassium reabsorption and increasing fecal potassium excretion. This mechanism allows for reduction of hyperkalemia without systemic absorption, making it suitable for chronic management of elevated serum potassium levels in patients taking medications that increase potassium retention.
Approved indications
- Hyperkalemia in patients with chronic kidney disease or heart failure on renin-angiotensin-aldosterone system inhibitors
Common side effects
- Hypomagnesemia
- Constipation
- Nausea
- Abdominal discomfort
Key clinical trials
- Patiromer and Diet/hrQoL in Chronic Dialysis (PHASE3)
- Comparison of Potassium Binders in the ER (PHASE4)
- Patiromer Efficacy to Reduce Episodic Hyperkalemia in End Stage Renal Disease Patients (PHASE4)
- Patiromer Trial in CKD Stage IIIB to V (PHASE3)
- Patiromer Utility as an Adjunct Treatment in Patients Needing Urgent Hyperkalemia Management (PHASE4)
- A Pilot Trial of Twice-weekly Versus Thrice-weekly Hemodialysis in Patients With Incident End-stage Kidney Disease (PHASE3)
- Effects of Patiromer on Pharmacokinetics of Immunosuppresive Drugs in Renal Transplant Recipients (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Patiromer Oral Product CI brief — competitive landscape report
- Patiromer Oral Product updates RSS · CI watch RSS
- Wake Forest University Health Sciences portfolio CI
Frequently asked questions about Patiromer Oral Product
What is Patiromer Oral Product?
How does Patiromer Oral Product work?
What is Patiromer Oral Product used for?
Who makes Patiromer Oral Product?
Is Patiromer Oral Product also known as anything else?
What drug class is Patiromer Oral Product in?
What development phase is Patiromer Oral Product in?
What are the side effects of Patiromer Oral Product?
What does Patiromer Oral Product target?
Related
- Drug class: All Potassium binder drugs
- Target: All drugs targeting Potassium ion (K+) in gastrointestinal lumen
- Manufacturer: Wake Forest University Health Sciences — full pipeline
- Therapeutic area: All drugs in Cardiovascular
- Indication: Drugs for Hyperkalemia in patients with chronic kidney disease or heart failure on renin-angiotensin-aldosterone system inhibitors
- Also known as: Valtressa
- Compare: Patiromer Oral Product vs similar drugs
- Pricing: Patiromer Oral Product cost, discount & access